Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study

NCT05180851 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Melanoma
Breast Cancer
Bladder Cancer
Ovarian Carcinoma
Cervical Carcinoma
Lung Cancer

Interventions

DRUG: Recombinant L-IFN adenovirus injection

Sponsor

Shanghai Fengxian District Central Hospital

Collaborators

[object Object]